The short answer
Aluminum-containing antacids can interfere with bictegravir absorption. For Biktarvy, take the HIV medicine at least 2 hours before or 6 hours after an aluminum/magnesium antacid. A two-hour gap in either direction is not equivalent, and food does not remove this antacid interaction.
What this answer covers
Adult oral bictegravir in Biktarvy and aluminum-containing antacids. Direct research used aluminum hydroxide combined with magnesium hydroxide; isolated aluminum products, dietary aluminum and other formulations were not separately tested.
- Supplement or preparation
- Aluminum
- Medication ingredient
- bictegravir
Why does the timing matter?
Bictegravir can bind certain metal ions in the digestive tract, leaving less medicine available for absorption. A study using an aluminum hydroxide and magnesium hydroxide antacid found about 79% lower bictegravir exposure when both products were taken together fasting. This was a combined antacid, so the result cannot tell us how much of the effect came from aluminum alone.
Which schedule should I follow?
The current U.S. Biktarvy label says to take Biktarvy at least two hours before or six hours after an aluminum/magnesium antacid. In the study, taking Biktarvy two hours after the antacid still left exposure about 52% lower. Reversing the order therefore changes the answer. These instructions also apply when deciding how to fit an occasional heartburn treatment around the daily HIV medicine.
Does taking it with food solve the problem?
Food does not provide the same solution for aluminum/magnesium antacids that it does for calcium or iron with Biktarvy. Exposure remained lower when the combined antacid was taken with a meal. That comparison used Biktarvy alone fasting as the reference, but it still supports retaining the label’s antacid timing rule. Check all active ingredients rather than relying on a product’s heartburn-relief brand name.
What should I check with my HIV pharmacist?
Bring the antacid label and your usual medication schedule. The pharmacist can distinguish an aluminum/magnesium antacid from a calcium product or another stomach medicine and help choose a workable schedule. Continue Biktarvy as prescribed; do not skip doses to make room for an antacid. If the products have repeatedly been taken together, tell your HIV team so they can assess adherence and viral-load follow-up.
Evidence and practical considerations
Absorption & effectiveness
Aluminum-containing antacids can interfere with bictegravir absorption. For Biktarvy, take the HIV medicine at least 2 hours before or 6 hours after an aluminum/magnesium antacid. A two-hour gap in either direction is not equivalent, and food does not remove this antacid interaction.
- Exact scope
- Adult oral bictegravir in Biktarvy and aluminum-containing antacids. Direct research used aluminum hydroxide combined with magnesium hydroxide; isolated aluminum products, dietary aluminum and other formulations were not separately tested. with Adult oral bictegravir as Biktarvy 50/200/25 mg fixed combination
- Medication form and route
- Adult oral bictegravir as Biktarvy 50/200/25 mg fixed combination; oral mineral, supplement or antacid within stated preparation scope
- Timing or duration
- Single-dose pharmacokinetic study with simultaneous or separated antacid exposure; current labeling governs ongoing treatment. Chronic virologic outcome rates were not measured.
What remains uncertain
- The trial cannot isolate aluminum from coadministered magnesium. A reduction in drug exposure is not a quantified treatment failure rate; non-antacid aluminum products need individual assessment.
Factors that may matter: Exact mineral ingredients, preparation and elemental amount; Biktarvy fixed-combination formulation; Food and direction of administration when applicable; Concurrent mineral products, adherence and viral-load monitoring.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People using the fixed combination Biktarvy for HIV treatment; adult-strength tablets contain bictegravir 50 mg, emtricitabine 200 mg and tenofovir alafenamide 25 mg.
Give Biktarvy at least 2 hours before or 6 hours after aluminum/magnesium antacids. Calcium or iron can be taken together with food; routine simultaneous fasting administration or Biktarvy 2 hours after calcium/iron is not recommended. St. John’s wort coadministration is not recommended because bictegravir and tenofovir alafenamide may decrease.
How this applies: Exact bictegravir active ingredient is bridged from bictegravir sodium by the label’s declared equivalent dose. Cation findings concern bictegravir; St. John’s wort can also affect the tenofovir alafenamide component. No emtricitabine interaction is inferred. Exact article scope: Adult oral bictegravir in Biktarvy and aluminum-containing antacids. Direct research used aluminum hydroxide combined with magnesium hydroxide; isolated aluminum products, dietary aluminum and other formulations were not separately tested.
Combination-product labeling, not evidence for bictegravir monotherapy. Named antacid directions are not direct experiments on every nutritional magnesium/aluminum formulation. The label supplies no echinacea trial or measured interaction for every multivitamin. Pregnancy has explicit additional fasting instructions.
Source 2: U.S. expert clinical treatment guideline
clinicalinfo.hiv.gov · Source check Sep 10, 2026
Population: Adults and adolescents receiving integrase inhibitor regimens for HIV.
Bictegravir mineral directions depend on cation and food. If raltegravir must be used with polyvalent mineral supplements, give it at least 2 hours before or 6 hours after and monitor virologic response. Multivitamin chelation magnitude is uncertain. Raltegravir antacid rules are separate: avoid Al/Mg, and distinguish calcium carbonate 400 mg twice daily from 1,200 mg once daily. Do not coadminister bictegravir with St. John’s wort.
How this applies: Exact-drug management guidance. Bictegravir sodium and raltegravir potassium are interpreted through their labels’ active-moiety equivalents. Calcium/iron food exceptions for bictegravir do not transfer to raltegravir. Exact article scope: Adult oral bictegravir in Biktarvy and aluminum-containing antacids. Direct research used aluminum hydroxide combined with magnesium hydroxide; isolated aluminum products, dietary aluminum and other formulations were not separately tested.
Expert recommendations include predicted interactions where exact-pair clinical studies are absent. A suggested supplement schedule does not supersede the distinct antacid avoidance instructions. No universal safe dose or virologic risk percentage is established.
Source 3: peer-reviewed prospective human pharmacokinetic study
europepmc.org · Source check Sep 10, 2026
Population: 42 healthy HIV-negative adults aged 18-45 years, in three cohorts of 14; open-label single-dose study conducted in 2016.
Fasted simultaneous bictegravir exposure was lower by 79% with combined Al/Mg antacid, 33% with calcium carbonate and 63% with ferrous fumarate. Bictegravir 2 hours before Al/Mg largely preserved exposure; 2 hours after still reduced it by 52%. With food, calcium exposure ratio was 1.033 and iron ratio 0.838 relative to bictegravir alone fasting; Al/Mg still reduced exposure by 47%.
How this applies: Direct preparation-specific evidence for adult oral bictegravir in Biktarvy. Calcium carbonate and ferrous fumarate findings are explicitly bounded within broader calcium and iron articles. These data do not directly measure every multivitamin, magnesium chelate or aluminum product. Exact article scope: Adult oral bictegravir in Biktarvy and aluminum-containing antacids. Direct research used aluminum hydroxide combined with magnesium hydroxide; isolated aluminum products, dietary aluminum and other formulations were not separately tested.
Single doses in healthy people, not a clinical failure trial. Combined Al/Mg does not isolate either ion. Fed combination arms were compared with a fasted-alone reference, not fed-alone control. Sponsor Gilead participated in design, analysis and writing. Discussion language about regional timing differs from the current U.S. label; the U.S. 2-before/6-after antacid instructions govern the article.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact-drug labeling and guidance checked; original human studies and neutral findings assessed. Current statements adjudicated with formulation, food and directional timing corrections. Article written; clinical sign-off not recorded. | |
| Research summary published |
Article revision: d44f0523614c22cb
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.